Analyst initiated coverage on Ascentage Pharma
$AAPG
Biotechnology: Pharmaceutical Preparations
Health Care
Analyst initiated coverage of Ascentage Pharma with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/13/2026 | $48.00 | Buy | Rodman & Renshaw |
| 12/4/2025 | $45.00 | Outperform | Oppenheimer |
| 11/24/2025 | Buy | Truist | |
| 11/10/2025 | $50.00 | Buy | BTIG Research |
| 11/5/2025 | $48.00 | Overweight | Piper Sandler |
| 3/27/2025 | Overweight | Analyst |
ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation Bruton's tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) application clearance from the China Center for Drug Evaluation (CDE) and is poised to enter a clinical study in patients with relapsed/refractory hematologic malignancies. This IND clearance from the China CDE
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, propelling expansion of global innovative pipelineMultiple global registrational Phase III trials are progressing rapidly ROCKVILLE, Md. and SUZHOU, China, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its Cha
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company's global innovative pipeline.Ascentage Pharma will conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies. ROCKVILLE, Md. and SUZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in canc
Rodman & Renshaw initiated coverage of Ascentage Pharma with a rating of Buy and set a new price target of $48.00
Oppenheimer initiated coverage of Ascentage Pharma with a rating of Outperform and set a new price target of $45.00
Truist initiated coverage of Ascentage Pharma with a rating of Buy
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six months 2025 unaudited interim results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on August 20, 2025 / 7:00 am Hong Kong Time (HKT) on August 21, 2025. Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company's management team. Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on Aug
ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by the Ascentage management team. The English conference call and webcast will be he